Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of ribavirin solution versus capsules
NL-OMON36756Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ribavirin in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoints: Pharmacokinetics and Safety. Started May 2011; status: active, not recruiting.
02
Drugs
ribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON36756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36756.